Hypera S.A. Hypera S.A.

Hypera S.A.

HYPE3

株式のランク #4245
Based in São Paulo, Brazil, Hypera S.A. is a prominent pharmaceutical... Based in São Paulo, Brazil, Hypera S.A. is a prominent pharmaceutical enterprise. The company's comprehensive product line encompasses a wide array of prescription medications, featuring established brands such as Adacne, Celestamine, Cizax, Diprosone, and Emprol XR, among many others. Beyond prescription drugs, Hypera offers specialized dermo-cosmetics through its Mantecorp Skincare brand. Its consumer health division markets popular remedies like Apracur, Benegrip, Engov, and Estomazil. Additionally, Hypera provides nutritional and vitamin supplements, including well-known names such as Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal. The company also maintains a significant presence in the generic and similar medicines market, offering products under the Neo Química brand and common formulations like Ibuprofen, Paracetamol, and Omeprazole. The organization officially became Hypera S.A. in February 2018, having previously operated as Hypermarcas S.A.
株価
$5.31
時価総額
$3.74B
変化(1日)
1.78%
変化(1年)
24.80%
国
BR
取引 Hypera S.A. (HYPE3)

カテゴリー

Healthcare
Hypera S.A.(HYPE3)の利益
2026 時点の利益 TTM: 0
Hypera S.A. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Hypera S.A. の利益の推移(2026 〜 2026)
各年末の利益
年 利益 変化
提供された日付のデータは十分ではありません。